4:27 pm - Monday September 25, 2017

FDA approval of medical MJ: phase I human studies explored by team of experts

 Recent appointees to a team of experts will explore the safety data required for Institutional Review Board (IRB) and FDA approval of human (Phase I, II, III) studies on the use of medicinal marijuana

Brent A. Reynolds PhD, and Dennis A. Steindler PhD will focus on the Federal requirements necessary for approval to market medicinal marijuana drugs in legal communities.  As newly appointed Directors,  Drs. Reynolds and Steindler will run and manage the  Discovery Research & Development division of United Cannabis Corporation. The Doctors will establish evidence of cannabis-based medical efficacy, and create Intellectual Property (IP) on medically efficient cannabinoid-based products  

Exploring the medical applications of cannabinoids, the Doctors will focus on IP claims, protecting products and their application, pre-clinical exploratory, proof of principal, and the safety data required for Institutional Review Board (IRB) and FDA approval of human (Phase I, II, III) studies on the use of medicinal marijuana.

Dr. Reynolds treats diseases and dysfunction of the nervous system. Dr. Steindler diagnoses and treats neurodegenerative diseases and cancer. Drs. Reynolds and Steindler have a record of patent protection and product development.

“Based on the evidence and efficacy of our programs, we are building a foundation established on human studies. United Cannabis will seek out the science behind full spectrum cannabinoids to develop synergistic medicine that compliments conventional therapies. The Company now has an opportunity that not only allows us to research the plant, but with the recently appointed expert team of Drs. Reynolds and Steindler, we can convert those findings into realized products FDA approved for medical applications,” notes Tony Verzura, VP United Cannabis Corporation.

Comments

comments

Filed in: health / salud